AR046465A1 - Formas de dosificacion de liberacion controlada de azitromicina - Google Patents

Formas de dosificacion de liberacion controlada de azitromicina

Info

Publication number
AR046465A1
AR046465A1 ARP040104510A ARP040104510A AR046465A1 AR 046465 A1 AR046465 A1 AR 046465A1 AR P040104510 A ARP040104510 A AR P040104510A AR P040104510 A ARP040104510 A AR P040104510A AR 046465 A1 AR046465 A1 AR 046465A1
Authority
AR
Argentina
Prior art keywords
multiparticles
azithromycin
release
pharmaceutically acceptable
side effects
Prior art date
Application number
ARP040104510A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR046465A1 publication Critical patent/AR046465A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen un procedimiento para formar multipartículas de azitromicina y una forma de dosificación de liberación controlada que comprende multipartículas de azitromicina y un excipiente farmacéuticamente aceptable. La forma de dosificación disminuye la incidencia y/o gravedad de los efectos secundarios GI con relación a las formas de dosificación de azitromicina de liberación inmediata actualmente disponibles que liberan una dosis equivalente. Las formas de dosificación actúan efectuando la liberación de azitromicina a una velocidad suficientemente lenta para mejorar los efectos secundarios, aunque suficientemente rápida para lograr buena biodisponibilidad. Reivindicación 1: Un procedimiento para la formación de multipartículas que comprende las etapas de: a) formar una mezcla fundida que comprende azitromicina, un vehículo farmacéuticamente aceptable y un potenciador opcional de disolución; b) distribuir dicha mezcla fundida de la etapa (a) a un medio de atomización para formar gotitas de dicha mezcla; c) congelar las gotitas de la etapa (b) para formar las multipartículas; y d) tratar posteriormente las multipartículas de manera que se incremente el grado de cristalinidad de la azitromicina en las multipartículas.
ARP040104510A 2003-12-04 2004-12-03 Formas de dosificacion de liberacion controlada de azitromicina AR046465A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52731703P 2003-12-04 2003-12-04

Publications (1)

Publication Number Publication Date
AR046465A1 true AR046465A1 (es) 2005-12-07

Family

ID=34652491

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104510A AR046465A1 (es) 2003-12-04 2004-12-03 Formas de dosificacion de liberacion controlada de azitromicina

Country Status (4)

Country Link
US (1) US20050123615A1 (es)
AR (1) AR046465A1 (es)
TW (1) TW200526270A (es)
WO (1) WO2005053654A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513145A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 医薬用多微粒子の製造方法
CN102824311A (zh) * 2012-09-11 2012-12-19 广西禾力药业有限公司 掩盖苦味的阿奇霉素颗粒
EP2964243B1 (en) 2013-03-06 2022-11-23 Capsugel Belgium NV Curcumin solid lipid particles and methods for their preparation and use
WO2016087261A1 (en) * 2014-12-04 2016-06-09 Capsugel Belgium N.V. Lipid multiparticulate formulations
GB201716419D0 (en) 2017-10-06 2017-11-22 Univ Central Lancashire Solid composition
CN111643455A (zh) * 2020-06-22 2020-09-11 健民药业集团股份有限公司 一种阿奇霉素缓释干混悬剂及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9605419A (es) * 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.

Also Published As

Publication number Publication date
WO2005053654A1 (en) 2005-06-16
US20050123615A1 (en) 2005-06-09
TW200526270A (en) 2005-08-16

Similar Documents

Publication Publication Date Title
CY1121812T1 (el) Φαρμακοτεχνικη μορφη ταχειας διαλυτοποιησης η οποια περιλαμβανει σινακαλσετη hcl
ES2531323T3 (es) Método para producir productos farmacéuticos
AR046749A1 (es) Procedimiento de extrusion para formar farmacos multiparticulados quimicamente estables.
ES2191977T3 (es) Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
UY26799A1 (es) Método para preparar un compuesto
JP2012513412A5 (es)
WO2005065185A3 (en) Temperature-stable formulations, and methods of development thereof
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
JP2009536147A5 (es)
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
EA200401583A1 (ru) Таблетка лазофоксифена и ее покрытие
WO2007011878A3 (en) Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
CL2004001372A1 (es) Alendronato monosodico en forma amorfa; proceso de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la resorcion osea en el tratamiento de fracturas, osteoporosis, osteoartritis, enfermedad de paget, osteohalisteresis, os
WO2005002582A3 (en) Trp-p8 active compounds and therapeutic treatment methods
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
JP2005213260A5 (es)
AR076864A1 (es) Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos
AR107392A1 (es) Formulaciones / composiciones que comprenden un inhibidor de btk
AR046465A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
UY26720A1 (es) Derivados del pirrol
ATE542526T1 (de) Niedrigdosierte tabletten mit einem polymernetz
WO2004069145A3 (en) Anticancer compounds, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FB Suspension of granting procedure